Fri, Dec 26, 2014, 4:13 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Rockwell Medical, Inc. Message Board

tburress40 5 posts  |  Last Activity: Jun 8, 2013 9:08 PM Member since: Dec 29, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Amgen BuyOut?

    by tburress40 Jun 8, 2013 9:06 PM
    tburress40 tburress40 Jun 8, 2013 9:08 PM Flag

    There is still more work to be done, said Ziad Massy, MD, professor of nephrology at Ambroise Paré Hospital in Paris, France, who attended the session.

    "Depending on how much iron you deliver and how fast you deliver it, the concern is always that you can increase oxidative stress. We need more data on the safety of this delivery method, especially for oxidative stress markers," Dr. Massy told Medscape Medical News. However, he acknowledged, "Dr. Gupta said he is going to do it."

    Sentiment: Buy

  • tburress40 by tburress40 Jun 8, 2013 9:06 PM Flag

    "Soluble ferric pyrophosphate significantly reduces the need for erythropoiesis-stimulating agents and intravenous iron agents without an intravenous iron source. It appears very safe," said Dr. Gupta.

  • Knockdown of MANF expression with antisense splice-blocking morpholino oligonucleotides resulted in no apparent abnormal phenotype. Nevertheless, the dopamine level of MANF morphants was lower than that of the wild type larvae, the expression levels of the two tyrosine hydroxylase gene transcripts were decreased and a decrease in neuron number in certain groups of th1 and th2 cells in the diencephalon region in MANF morphants was observed. These defects were rescued by injection of exogenous manf mRNA. Strikingly, manf mRNA could partly restore the decrease of th1 positive cells in Nr4a2-deficient larvae. These results suggest that MANF is involved in the regulation of the development of dopaminergic system in zebrafish.

    Sentiment: Hold

  • Reply to

    Neurotrophic Factors Challenge 2012

    by tburress40 Dec 29, 2012 9:49 AM
    tburress40 tburress40 Dec 29, 2012 9:52 AM Flag

    Given that several rodent studies have shown that neurotrophic factors are not effective in alpha-synuclein models MJFF is interested in projects aimed at understanding the interactions between neurotrophic factors and alpha-synuclein that could inform future therapeutic strategies.

    MJFF continues to be interested in novel neurotrophic factors that may be more efficacious than known neurotrophic factors or possess properties, such as brain penetrability, that make them more desirable as potential therapeutics.

    The delivery of neurotrophic factors continues to be problematic and invasive. MJFF would like to support efforts to develop noninvasive approaches to deliver neurotrophic factors to the brain

    Sentiment: Hold

  • In the last several years both preclinical studies and several early Phase clinical trials using neurotrophic factors have showed promise. However, neurotrophic factor therapies have not yet been demonstrated to be safe and efficacious in Phase II clinical trials. While previous clinical trials yielded inconclusive results, many unanswered questions remain about the potential of neurotrophic factors as therapies for PD and vigorous interest remains in further developing neurotrophic factor therapies.

    MJFF continues to regard neurotrophic factor therapy as a promising approach that deserves additional rigorous investigation in the hopes of advancing the field from promise to reality or at least in definitively determining the viability of the approach.

    Sentiment: Hold

RMTI
8.615+0.205(+2.44%)3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.